5099-39-8

Upstream product

• 56223-91-7 N’-(2,4-dinitrophenyl)-N,N-diethylethane-1,2-diamine 
• 97-00-7 1-chloro-2,4-dinitro-benzene 
• 100-36-7 N,N-diethylethylenediamine 
• 16830-65-2 N-(2-chloroethyl)-2,4-dinitrobenzenamine 
• 1945-92-2 N-(2,4-dinitrophenyl)aminoethanol 

Downstream Products

• 14030-71-8 [2-(2-benzyl-5-nitro-benzoimidazol-1-yl)-ethyl]-diethyl-amine 
• 94760-41-5 2-(4-chloro-phenyl)-2-[1-(2-diethylamino-ethyl)-5-nitro-1H-benzoimidazol-2-yl]-acetamide 
• 3861-76-5 clonitazene 
• 110150-36-2 2-(4-chlorobenzyl)-1-[2-(diethylamino)ethyl]-1H-benzo[d]imidazol-5-amine 
• 95810-54-1 butonitazene 
• 14188-81-9 isotonitazene 
• 14680-51-4 metonitazene 
• 94758-81-3 4-((1-(2-(diethylamino)ethyl)-5-nitro-1H-benzo[d]imidazol-2-yl)-methyl)phenol 
• 75821-80-6 1-[2-(diethylamino)ethyl]-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-amine 
• 911-65-9 etonitazene 

Relevant academic research and scientific papers

Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of "nitazene" 2-Benzylbenzimidazole Synthetic Opioids

Several 2-benzylbenzimidazole opioids (also referred to as "nitazenes") recently emerged on the illicit market. The most frequently encountered member, isotonitazene, has been identified in multiple fatalities since its appearance in 2019. Although recent

Synthesis and molecular docking for antiinflammatory studies of 2-(arylmethyl)-1-ethyl-1H-benzo[d]imidazol-5-amines

1-Chloro-2,4-dinitrobenzene (1) was reacted with aliphatic amines (2) in ethanol as solvent under reflux condition for 16-24 h to form N-alkyl-2,4-dinitroaniline (3). Compound 3 undergoes reduction to from N-alkyl-4-nitrobenzene-1,2-diamine (4). Compound 4 was treated with carboxylic acid (5) to offered N-(2-(alkylamino)-5-nitrophenyl)-2-arylacetamide (6) which on cyclization gave 2-(arylmethyl)-1-ethyl-5-nitro-1H-benzo[d]imidazole (7). Finally, compound 7 undergoes reduction give 2-(arylmethyl)-1-ethyl-1H-benzo[d]imidazol-5-amine (8). The synthesized compounds were characterized by using spectral analyses. The compounds synthesized were confirmed by spectral analyses. Molecular docking of 5COX with the ligand using docking server, predicted the compound to be a potential anti-inflammatory compound.

NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity

A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the μ-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the μ-opioid GPCR was predicated on the modulatory role of nitric oxide on μ-opioid receptor function. Structure-activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 μM), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent μ-opioid binding affinity, Ki = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 μM). This work represents a novel approach in the development of new analgesics for the treatment of pain.

Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.